Crosscheck

Your medical. Crosschecked.

Other

Vedolizumab and your FAA medical

Selective adhesion-molecule (SAM) inhibitor, biologic
Other names: Entyvio

FAA guidance

Acceptable with conditions.

Wait

2 weeks

ground trial when starting

Different waits apply in other cases.

Examiner

The examiner can issue when the document's criteria are met

FAA label

ACCEPTABLE

Source: FAA, Biologics, Biosimilars, and Non-Biologics. FAA date 26 August 2026. Checked by Crosscheck 11 November 2026

The FAA lists vedolizumab as an acceptable biologic when the underlying condition qualifies, with a two-week ground trial when starting and four hours of no-fly after each dose.

Track your medications
More detail: vedolizumabThe rest of Crosscheck's reading, in plain wordsOpen

Wait

  • 4 hours no-fly after each dose
  • a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication

Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.

  • 14 days after starting: ground observation
  • 4 hours after each dose: no flying
Show the FAA's words: vedolizumabThe official FAA wording: two passages, each with its document and dateOpen
FAA, Biologics, Biosimilars, and Non-Biologics · FAA date 26 August 2026
Observation times: Required ground trial and/or no-fly after each dose. Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
ACCEPTABLE BIOLOGICS - MONOTHERAPY MEDICATION Permitted if the underlying condition qualifies; consult the condition pages for details.
Selective Adhesion-Molecule (SAM) Inhibitor: vedolizumab (Entyvio), 4 hours
FAA, Biologics, Biosimilars, and Non-Biologics · FAA date 26 August 2026
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.
Sources and dates: vedolizumabOne FAA document, with the FAA's date and when Crosscheck checked itOpen

Questions pilots ask

Each answer is built from the FAA guidance on this page. Its sources and dates are in the page.

What does the FAA say about vedolizumab for pilots?

FAA guidance: Acceptable with conditions. The FAA lists vedolizumab as an acceptable biologic when the underlying condition qualifies, with a two-week ground trial when starting and four hours of no-fly after each dose. Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial. Crosscheck does not predict the FAA's decision.

How long is the FAA's wait for vedolizumab?

2-week ground trial when starting; 4 hours no-fly after each dose; a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication.

What does the examiner do for vedolizumab?

The examiner can issue when the document's criteria are met. Crosscheck does not predict the FAA's decision.

Related pages

Medication guidance alone does not determine whether a pilot is medically qualified to fly. The underlying condition, dosage, side effects, medication combinations, and certification history may affect FAA eligibility.

For informational purposes only. Not legal or medical advice.